Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DECODE GENETICS-*DCGN -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (259)	10/8/2006 11:28:02 AM
From: tommysdad	Respond to of 313

Lame? Lordy no. I think it is precisely how many management teams (not only at biotechs!) would look at the situation. Which drives scientists absolutely nuts, since the situation is often not so clear-cut. I guess what I left unsaid is that I think a scenario that is much more likely than deCode dropping the FLAP inhibitor in favor of the LTA4H inhibitor, is deCode partnering the proprietary molecule. It may be difficult to find a partner for a drug that they licensed from Bayer, and, as you noted, it will be difficult for them to fund both programs. (Two years, really? Yikes.)